SYA dark blue font on white background (1).jpg
Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncology
December 05, 2023 12:26 ET | Syapse
Research collaboration between Syapse and the FDA Oncology Center of Excellence extended to assess fit-for-purpose RWD and explore the potential of RWE.
SYA dark blue font on white background (1).jpg
Custom Research Presented at AMIA Informatics Summit Reveals Promising Findings for Healthcare Innovation
March 14, 2023 08:05 ET | Syapse
SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
SYA dark blue font on white background (1).jpg
Syapse Enters Collaboration with Merck Using Real-World Evidence to Better Understand Cancers
September 15, 2022 08:00 ET | Syapse
SAN FRANCISCO and NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing...
SYA dark blue font on white background (1).jpg
Syapse and Genesis Research Combine Forces to Offer Real-World Evidence Services and Data to Oncology Innovators
August 31, 2022 08:00 ET | Syapse
SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...
SYA dark blue font on white background (1).jpg
Syapse Announces $35 Million Growth Investment with Innovatus Capital Partners to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network
July 27, 2022 09:00 ET | Syapse
SAN FRANCISCO and NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing...
SYA dark blue font on white background (1).jpg
Syapse and Pierian Announce Genomics Collaboration to Power Precision Oncology
June 14, 2022 10:00 ET | Syapse
SAN FRANCISCO, June 14, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company announced with Pierian®, a global leader in advanced clinical genomics technology, a new joint...
SYA dark blue font on white background (1).jpg
Syapse Unveils Two New Studies on Use of Machine Learning on Real-World Data to Identify and Treat Cancer With Precision at ASCO 2022
May 27, 2022 10:00 ET | Syapse
SAN FRANCISCO, May 27, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...
SYA dark blue font on white background (1).jpg
Syapse Announces Changes to Board of Directors, Adding Michael Mentesana and Elevating Frank Williams to Chairman Role
March 31, 2022 10:00 ET | Syapse
SAN FRANCISCO, March 31, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
SYA dark blue font on white background (1).jpg
Main Line Health Collaborates with Syapse, Bringing Clinical Trial Opportunities to Patients with Cancer in Philadelphia Region
March 22, 2022 10:00 ET | Syapse
SAN FRANCISCO, March 22, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
SYA dark blue font on white background (1).jpg
Syapse Extends Collaboration with Pfizer to Continue to Generate Real-World Evidence in Breast Cancer
January 20, 2022 10:00 ET | Syapse
SAN FRANCISCO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...